Monoclonal antibodies (mAbs)
In the last decade, approximately 40 novel mAbs have begun clinical studies each year, and new products are regularly approved by regulatory agencies.
The structure of mAbs is extremely complicated and dynamic, so it can be challenging to establish well-characterized antibody therapeutics to meet current regulatory expectations. Based on their extensive knowledge, AMSbiopharma scientist offers a tailor-made plan that ensures correct structural and purity/impurities characterization for your developed mAb:
Also, related to the use of therapeutic monoclonal antibodies (mAbs) in preclinical studies, AMSbiopharma offers a quantitative analysis of mAbs in animal biological matrices by HPLC-MS/MS.